Compare BNTX & CNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNTX | CNC |
|---|---|---|
| Founded | 2008 | 1984 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.8B | 21.5B |
| IPO Year | 2019 | 2001 |
| Metric | BNTX | CNC |
|---|---|---|
| Price | $88.47 | $35.87 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 17 |
| Target Price | ★ $134.15 | $41.75 |
| AVG Volume (30 Days) | 1.2M | ★ 4.9M |
| Earning Date | 03-10-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $194,777,000,000.00 |
| Revenue This Year | N/A | $8.11 |
| Revenue Next Year | $2.61 | $1.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.44 |
| 52 Week Low | $79.81 | $25.08 |
| 52 Week High | $124.00 | $66.03 |
| Indicator | BNTX | CNC |
|---|---|---|
| Relative Strength Index (RSI) | 35.78 | 35.61 |
| Support Level | $79.81 | $33.27 |
| Resistance Level | $112.30 | $38.67 |
| Average True Range (ATR) | 3.55 | 1.43 |
| MACD | -1.04 | -0.63 |
| Stochastic Oscillator | 28.52 | 17.63 |
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.